Sort by

(S)-Carbidopa ethyl ester

  • CAT Number DCTI-C-764
  • CAS Number 1458640-32-8
  • Molecular Formula C12H18N2O4
  • Molecular Weight 254.29

(S)-Carbidopa methyl ester

  • CAT Number DCTI-C-1213
  • CAS Number 52514-63-3 (Free Base)
  • Molecular Formula C11H17ClN2O4 (HCl Salt) C11H16N2O4 (Free base)
  • Molecular Weight 276.72 (HCl Salt) 240.26 (Free base)

3-Methylcinnoline-6,7 diol

  • CAS NUMBER 1176784-51-2

Carbidopa EP Impurity C

  • CAT Number DCTI-C-888
  • CAS Number 85933-19-3
  • Molecular Formula C11H16N2O4
  • Molecular Weight 240.26

Carbidopa EP Impurity H

  • CAT Number DCTI-C-922
  • CAS Number 2470439-16-6 (RACEMIC) ; 1361017-74-4(S-ISOMER)
  • Molecular Formula C11H16N2O4
  • Molecular Weight 240.26

Carbidopa EP Impurity I

  • CAT Number DCTI-C-707
  • CAS Number 1246819-09-9
  • Molecular Formula C10H13BrN2O4
  • Molecular Weight 305.13

Carbidopa EP Impurity J

  • CAT Number DCTI-C-840
  • CAS Number 1246817-47-9
  • Molecular Formula C10H13BrN2O4
  • Molecular Weight 305.13

N-Nitroso Carbidopa Acetate Salt

  • MOLECULAR FORMULA Free Acid: C10H13N3O5 Acetate Salt: Chemical Formula: C12H17N3O7-
  • MOLECULAR WEIGHT Free Acid: 255.23 Acetate Salt: 315.28

General Information

Carbidopa Impurities and Carbidopa 

Daicel Pharma synthesizes high-quality Carbidopa impurities like (S)-Carbidopa ethyl ester, (S)-Carbidopa methyl ester, 3-Methylcinnoline-6,7 diol, Carbidopa EP Impurity C, Carbidopa EP Impurity H, Carbidopa EP Impurity I, and Carbidopa EP Impurity J, which are crucial in the analysis of the quality, stability, and biological safety of the active pharmaceutical ingredient Carbidopa. Moreover, Daicel Pharma offers custom synthesis of Carbidopa impurities and delivers them globally.

Carbidopa [CAS: 28860-95-9] is a medicine to treat Parkinson’s disease. It belongs to a class of drugs known as decarboxylase inhibitors. Carbidopa is a synthetic form of the neurotransmitter dopamine and is the levorotatory isomer of a hydrazine derivative.

Carbidopa: Use and Commercial Availability  

Carbidopa is a medication used in combination with levodopa to treat motor symptoms associated with Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism symptoms caused by carbon monoxide or manganese intoxication. It is added to levodopa formulations to decrease the conversion of levodopa to dopamine outside the brain, lower gastrointestinal side effects, and improve levodopa’s effectiveness in the central nervous system. Carbidopa is available under brand names like Dhivy, Duopa, Lodosyn, Rytary, Sinemet, and Stalevo.

Carbidopa Structure and Mechanism of Action Carbidopa Structure and Mechanism of Action

The chemical name of Carbidopa is L-α-Hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid. Its chemical formula is C10H14N2O4, and its molecular weight is approximately 226.23 g/mol.

Carbidopa inhibits peripheral decarboxylation of levodopa, the metabolic precursor of dopamine. It prevents levodopa from breaking down into dopamine in areas outside the brain, which helps decrease the harmful effects of levodopa on the body.

Carbidopa Impurities and Synthesis

During the manufacturing1,2 of Carbidopa, impurities form that can be harmful and must be carefully monitored and controlled during production. The factors that influence the formation of these impurities include reaction conditions, storage conditions, and the quality of raw materials used in the manufacturing process.

Daicel provides a Certificate of Analysis (CoA) for Carbidopa impurity standards, including (S)-Carbidopa ethyl ester, (S)-Carbidopa methyl ester, 3-Methylcinnoline-6,7 diol, Carbidopa EP Impurity C, Carbidopa EP Impurity H, Carbidopa EP Impurity I, and Carbidopa EP Impurity J. The CoA is issued from a cGMP-compliant analytical facility and contains complete characterization data, such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity3. Additional characterization data, such as 13C-DEPT and CHN, can be provided upon request. Daicel can also prepare any unknown Carbidopa impurity or degradation product. We give a complete characterization report on delivery.


Frequently Asked Questions

The methods used to detect and quantify impurities in Carbidopa include high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS). These methods can identify and measure impurities at low levels, typically in the parts per million (ppm) range.

The source of impurities in Carbidopa includes starting materials, reagents, catalysts, solvents, etc. The contamination also occurs during storage and transportation.

The impurities in Carbidopa vary between batches of the drug, depending on factors such as the manufacturing process, the quality of the starting materials, storage, and transportation. Therefore, it is essential to test each batch of Carbidopa for impurities and ensure that it meets the regulatory requirements before its use.

Carbidopa impurities are stored at a controlled room temperature between 2-8 ⁰C or as indicated on the Certificate of Analysis (CoA).

Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.

Back to Top
Product has been added to your cart